Skip to main content
letter
. 2020 Oct 28;80(4):543–545. doi: 10.1136/annrheumdis-2020-218582

Figure 1.

Figure 1

A typical case of a girl >25 kg who received an initial dose of 5 mg twice daily of Janus kinase inhibitor (JAKi) but required the maximum dose of 7.5 mg twice daily. She received this dose for 6 months, and the dose was gradually tapered. In the meantime, glucocorticoids were also tapered, and the patient showed an increased growth rate. (A) The typical skin lesions before treatment with JAKi. (B) Those lesions had mostly disappeared after treatment.